-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $35

Benzinga·12/19/2025 17:08:43
語音播報
Goldman Sachs analyst Matt Dellatorre maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $31 to $35.